NCT04827901View on ClinicalTrials.gov

XEN1101 for Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

October 3, 2024

Study Completion Date

November 7, 2024

Conditions
Major Depressive Disorder
Interventions
DRUG

XEN1101

two 10 mg capsules

DRUG

Placebo

matching placebo

Trial Locations (2)

10029

Icahn School of Medicine at Mount Sinai, New York

77030

Baylor College of Medicine, Houston

All Listed Sponsors
collaborator

Baylor College of Medicine

OTHER

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

James Murrough

OTHER

NCT04827901 - XEN1101 for Major Depressive Disorder | Biotech Hunter | Biotech Hunter